The burden of skeletal-related events in patients with prostate cancer and bone metastasis

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 1, 2015, Pages 17.e9-17.e18

  Roghmann, Florian ^a   Antczak, Carina ^b   McKay, Rana R ^c   Choueiri, Toni ^c   Hu, Jim C ^d   Kibel, Adam S ^c   Kim, Simon P ^e   Kowalczyk, Keith J ^f   Menon, Mani ^g   Nguyen, Paul L ^c   Saad, Fred ^b   Sammon, Jesse D ^g   Schmid, Marianne ^c   Sukumar, Shyam ^h   Sun, Maxine ^b   Noldus, Joachim ^a   Trinh, Quoc Dien ^c,g  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^g HENRY FORD HEALTH SYSTEM   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Charges; Mortality; NIS; Prostate cancer; Skeletal related event

Indexed keywords

ADULT; AGE; AGED; ARM DISEASE; ARTICLE; BONE METASTASIS; CANCER SURGERY; COMORBIDITY; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCULOSKELETAL DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RADIOTHERAPY; SPINAL CORD COMPRESSION; BONE TUMOR; CASTRATION RESISTANT PROSTATE CANCER; COST OF ILLNESS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SECONDARY;

AGED; BONE NEOPLASMS; COST OF ILLNESS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84922673899     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.09.010     Document Type: Article

References (31)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. [Epub 2013/01/22].
2. Johansson J.E., Holmberg L., Johansson S., Bergstrom R., Adami H.O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. J Am Med Assoc 1997, 277:467-471. [Epub 1997/02/12].
3. Popiolek M., Rider J.R., Andren O., Andersson S.O., Holmberg L., Adami H.O., et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 2013, 63:428-435. [Epub 2012/10/23].
4. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31:578-583. [Epub 2000/06/03].
5. Fidler I.J., Kim S.J., Langley R.R. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 2007, 101:927-936. [Epub 2006/12/21].
6. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164. [Epub 2005/01/14].
7. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst Monogr 2002, 94:1458-1468. [Epub 2002/10/03].
8. Oefelein M.G., Ricchiuti V., Conrad W., Resnick M.I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168:1005-1007. [Epub 2002/08/21].
9. Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755. [Epub 2009/08/13].
10. Logothetis C.J., Basch E., Molina A., Fizazi K., North S.A., Chi K.N., et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012, 13:1210-1217. [Epub 2012/11/13].
11. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197. [Epub 2012/08/17].
12. Nilsson S., Franzen L., Parker C., Tyrrell C., Blom R., Tennvall J., et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007, 8:587-594. [Epub 2007/06/05].
13. Koo K., Lam K., Mittmann N., Konski A., Dennis K., Zeng L., et al. Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases. Support Care Cancer 2013, 21:1785-1791. [Epub 2013/03/23].
14. NIS Introduction 2010; 2012:1-85.
15. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
16. Census Regions and Divisions of the United States; 2000:1-2.
17. Liu J.H., Zingmond D.S., McGory M.L., SooHoo N.F., Ettner S.L., Brook R.H., et al. Disparities in the utilization of high-volume hospitals for complex surgery. J Am Med Assoc 2006, 296:1973-1980. [Epub 2006/10/26].
18. Sun M., Bianchi M., Trinh Q.D., Abdollah F., Schmitges J., Jeldres C., et al. Hospital volume is a determinant of postoperative complications, blood transfusion and length of stay after radical or partial nephrectomy. J Urol 2012, 187:405-410. [Epub 2011/12/20].
19. Wilkinson G.S., Kuo Y.F., Freeman J.L., Goodwin J.S. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007, 99:1016-1024. [Epub 2007/06/29].
20. Patrick S.W., Schumacher R.E., Benneyworth B.D., Krans E.E., McAllister J.M., Davis M.M. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. J Am Med Assoc 2012, 307:1934-1940. [Epub 2012/05/02].
21. Andridge R.R., Little R.J. A review of hot deck imputation for survey non-response. Int Stat Rev 2010, 78:40-64. [Epub 2010/04/01].
22. Bureau of Labor Statistics of the U.S. Department of Labor, [accessed 02.01.13]. http://data.bls.gov/cgi-bin/cpicalc.pl.
23. Sammon J.D., Ghani K.R., Karakiewicz P.I., Bhojani N., Ravi P., Sun M., et al. Temporal trends, practice patterns, and treatment outcomes for infected upper urinary tract stones in the United States. Eur Urol 2013, 64(1):85-92. [Epub 2012/10/04].
24. Sathiakumar N., Delzell E., Morrisey M.A., Falkson C., Yong M., Chia V., et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011, 14:177-183. [Epub 2011/03/16].
25. Hagiwara M., Delea T.E., Saville M.W., Chung K. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 2013, 16:23-27. [Epub 2012/11/14].
26. Jayasekera J., Onukwugha E., Bikov K., Mullins C.D., Seal B., Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. PharmacoEconomics 2014, 32:173-191. [Epub 2014/01/18].
27. Delea T., McKiernan J., Brandman J., Edelsberg J., Sung J., Raut M., et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006, 4:341-347. [Epub 2006/08/09].
28. Carter J.A., Joshi A., Kaura S., Botteman M.F. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. J Med Econ 2011, 14:288-298. [Epub 2011/04/08].
29. Lipton A., Fizazi K., Stopeck A.T., Henry D.H., Brown J.E., Yardley D.A., et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012, 48:3082-3092. [Epub 2012/09/15].
30. Fizazi K., Carducci M., Smith M., Damiao R., Brown J., Karsh L., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822. [Epub 2011/03/01].
31. Huang J., Jatoi A. Morbidity and mortality in patients with cancer who become nonambulatory after spinal cord compression: a case series on end-of-life care. J Palliat Med 2009, 12:219-222. [Epub 2009/03/04].